The emerging role of dosimetry in theranostics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Theranostics is a rapidly growing field that is moving toward a more quantitative and individualized treatment strategy, particularly for therapeutic radiopharmaceuticals. 

Radiopharmaceuticals are compelling because they combine biology and radiation. Typically a small molecule or antibody binds to a molecular target on a cancer cell and carries various types of radiation directly to it, such as Lutathera for neuroendocrine cancers and Pluvicto for prostate cancer. 

One of the most important developments is the growing evidence that the radiation dose absorbed by a tumor predicts response and clinical outcomes. Through imaging-based dosimetry, we can measure uptake and estimate how much radiation reaches tumors and normal tissues, creating a path to personalize treatment rather than relying solely on standardized administration. 

Dosimetry as the next frontier 

Radiation oncologists have long understood that tumor control is tied to the delivered radiation dose. The same principle increasingly applies to radiopharmaceutical therapies. Pretreatment and post-treatment imaging may help determine whether a patient is likely to receive a meaningful tumor dose. 

For decades, pretreatment imaging has been used for patients with thyroid cancer who receive radioactive iodine, or RAI, to determine the initial treatment dose. More recently, post-treatment imaging has been used to map radiation doses in patients receiving transarterial radioembolization, or TARE, for liver cancer. 

If the field builds the evidence and infrastructure collaboratively, theranostics can more quickly become a precise and integrated part of cancer care and improve outcomes for our cancer patients.

Post-treatment imaging potentially can show how much of the agent a tumor has absorbed and identify lesions that may be undertreated and require other ablative approaches, such as stereotactic body radiation therapy or needle ablation. 

This evolution mirrors external beam radiation therapy, where treatment planning and dose optimization are central to balancing efficacy and toxicity. Patients can absorb and distribute radiopharmaceuticals differently based on a number of factors, such as differences in circulation, perfusion, tumor penetration, clearance, metabolism, and tumor biology, including the expression of the molecular target. 

As a result, lesions within the same patient may have markedly different uptake and subsequent response. Dosimetry gives us an opportunity to adjust treatment to that biology. 

One example is to adjust the dose of radiopharmaceutical at each cycle of treatment, utilizing imaging-based dosimetry. That being said, there is still a lot of work that needs to be done to understand the best timepoints for dosimetric analysis for each radiopharmaceutical and whether a single timepoint can provide a reasonable measure of response. Answering these questions will be essential to realizing the full potential of personalized radiopharmaceutical therapy.

Combining radiation modalities 

Heterogeneous uptake also creates a rationale for combining radiopharmaceutical therapy with external beam radiation. In metastatic disease, external beam radiation could supplement the dose delivered to relatively “cold” lesions. City of Hope investigators are studying this type of approach, including work combining a radiopharmaceutical with external beam radiation in leukemia.

Investigators across the field are also exploring approaches that include changing the route of administration, combining different types of radioactive molecules to carry a cytotoxic payload and using radiopharmaceuticals with DNA repair inhibitors, other targeted inhibitors or immunotherapy. 

Building the infrastructure to scale 

Realizing this potential will require close collaboration among nuclear medicine physicians, radiation oncologists, medical physicists, technologists, and clinical trial teams. Radiopharmaceutical trials require specialized facilities, radiation safety procedures, authorized users and compliance with state and federal requirements. 

To maximize the value of radiopharmaceutical clinical trials, additional resources are needed, including SPECT and PET imaging for dosimetric analysis and the ability to conduct pharmacokinetic and pharmacodynamic analyses of blood and other tissues. Those demands become more complex when studies open across multiple institutions. 

City of Hope’s national clinical trial network creates an opportunity to support common policies, regulatory oversight, and trial infrastructure across sites. Cooperative groups, including NRG Oncology and SWOG, have also established committees focused on theranostics, helping to create a pathway toward larger multicenter trials. 

Looking ahead 

Over the next five to 10 years, advances in imaging-based dosimetry, new molecular targets, and rational combinations likely will expand the role of radiopharmaceuticals across oncology. Standard-of-care agents are already delivered in outpatient settings. A greater limitation is the need to develop the trained workforce and multidisciplinary infrastructure needed to deliver treatment safely and at scale. 

To be clear, theranostics is not a replacement for established cancer treatments. Its distinctive promise is the ability to unite molecular targeting with radiation and quantify what reaches the tumor in a non-invasive fashion, providing new options for patients. 

If the field builds the evidence and infrastructure collaboratively, theranostics can more quickly become a precise and integrated part of cancer care and improve outcomes for our cancer patients. 


City of Hope® is one of the largest and most advanced cancer research and treatment organizations in the U.S. To learn more about City of Hope, visit: www.cityofhope.org. 

Discover the latest innovations in cancer research on City of Hope’s podcast, “On the Edge of Breakthrough: Voices of Cancer Research.” Available on Spotify, Apple Podcasts, and at cityofhope.org/edge-of-breakthrough. 

Terence M. Williams, MD, PhD
Professor and chair, Department of Radiation Oncology, City of Hope
Table of Contents

YOU MAY BE INTERESTED IN

Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
Terence M. Williams, MD, PhD
Professor and chair, Department of Radiation Oncology, City of Hope

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login